You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

RETIN-A-MICRO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Retin-a-micro patents expire, and what generic alternatives are available?

Retin-a-micro is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in RETIN-A-MICRO is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Retin-a-micro

A generic version of RETIN-A-MICRO was approved as tretinoin by PADAGIS US on December 24th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RETIN-A-MICRO?
  • What are the global sales for RETIN-A-MICRO?
  • What is Average Wholesale Price for RETIN-A-MICRO?
Drug patent expirations by year for RETIN-A-MICRO
Pharmacology for RETIN-A-MICRO
Drug ClassRetinoid
Paragraph IV (Patent) Challenges for RETIN-A-MICRO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RETIN-A-MICRO Gel tretinoin 0.04% 020475 1 2010-12-20
RETIN-A-MICRO Gel tretinoin 0.1% 020475 1 2010-07-08

US Patents and Regulatory Information for RETIN-A-MICRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch RETIN-A-MICRO tretinoin GEL;TOPICAL 020475-004 Oct 23, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch RETIN-A-MICRO tretinoin GEL;TOPICAL 020475-003 Jan 28, 2014 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for RETIN-A-MICRO

See the table below for patents covering RETIN-A-MICRO around the world.

Country Patent Number Title Estimated Expiration
Australia 591264 ⤷  Sign Up
South Korea 960013701 ⤷  Sign Up
Japan H01500756 ⤷  Sign Up
South Africa 8702665 ⤷  Sign Up
Canada 1310583 COMPOSITIONS POLYMERISABLES POUVANT SERVIR DE SUPPORT A DES MATIERES ACTIVES ETPROCEDE DE FABRICATION CORRESPONDANT (POLYMERIC CARRIER COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for RETIN-A-MICRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0617614 C300043 Netherlands ⤷  Sign Up PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
0617614 11/2001 Austria ⤷  Sign Up PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
1304992 CR 2013 00053 Denmark ⤷  Sign Up PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992 1390049-3 Sweden ⤷  Sign Up PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
1304992 92401 Luxembourg ⤷  Sign Up PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.